Drug Trial Radar · NCT00050960
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jul 13, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
612
Actual
Start
May 2002
Primary completion
Jul 2004
Study completion Mar 2005
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Jan 3, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.
Conditions
- Non-small Cell Lung Cancer
Interventions
bexarotene with carboplatin and paclitaxelDrug
bexarotene capsules (400 mg/m\^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.
carboplatin and paclitaxelDrug
carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From date of randomization to date of death
Locations
154 sites in 6 countries. Site status is shown where the registry gives one.
Montgomery Cancer Center, L.L.C.
Montgomery, Alabama
Arizona Clinical Research Center, Inc.
Tucson, Arizona
Bay Area Cancer Research Group, LLC
Concord, California
Compassionate Cancer Care Medical Group, Inc.
Fountain Valley, California
Pacific Coast Hematology/Oncology Medical Group, Inc.
Fountain Valley, California
California Cancer Care, Inc.
Greenbrae, California
Coast Hematology and Oncology Associates
Long Beach, California
Metropolitan Hematology/Oncology Medical Group
Los Angeles, California
Sant P. Chawla, Inc.
Los Angeles, California
UCLA Medical Center
Los Angeles, California
Sutter Gould Medical Foundation
Modesto, California
Medical Oncology Care Associates
Orange, California
Southern California Kaiser Permanente Medical Group
San Diego, California
Sharp Health Care
San Diego, California
UCSF/Mount Zion Comprehensive Cancer Center
San Francisco, California
Medical Group of North County, Inc., San Diego Cancer Center
Vista, California
Rocky Mountain Cancer Centers - Midtown
Denver, Colorado
Eastern Connecticut Hematology & Oncology
Norwich, Connecticut
Georgetown University Hospital
Washington D.C., District of Columbia
Washington Cancer Institute
Washington D.C., District of Columbia
Comprehensive Cancer Care Specialists of Boca Raton
Boca Raton, Florida
University of Florida/Jacksonville
Jacksonville, Florida
Watson Clinic
Lakeland, Florida
Oncology and Radiation Associates
Miami, Florida
Florida Cancer Institute
New Port Richey, Florida
Florida Oncology Associates
Orange Park, Florida
Cancer Centers of Florida, P.A.
Orlando, Florida
South Florida Oncology & Hematology Consultants
Plantation, Florida
Medical Oncology Associates of Augusta
Augusta, Georgia
Georgia Oncology Partners Research & Education Foundation
Marietta, Georgia
St. Luke's/Mountain State Tumor Institute (MSTI)
Boise, Idaho
Weiss Memorial Hospital
Chicago, Illinois
Northwest Oncology and Hematology, SC
Elk Grove Village, Illinois
Lutheran General Cancer Care Center
Park Ridge, Illinois
Oncology/Hematology Associates of Central Illinois, P.C.
Peoria, Illinois
Hematology Oncology Assoc. of Illinois
Skokie, Illinois
Central Indiana Cancer Centers
Indianapolis, Indiana
Cancer Care Center
New Albany, Indiana
Michiana Hematology-Oncology
South Bend, Indiana
Kansas City Oncology and Hematology Group, Kansas City Cancer Centers
Overland Park, Kansas
Showing 40 of 154 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.